Breast Cancer
Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
Published in Cancer Weekly, November 25th, 2008
Genomic Health, Inc. (NASDAQ:GHDX) announced the publication of results from a study indicating that Oncotype DX(R) Recurrence Score(R) results impact the way physicians treat early-stage breast cancer. The study, published in the October issue of the American Journal of Surgery, showed that treatment changed as a result of Oncotype DX in 44 percent of patients with node- negative estrogen receptor-positive breast cancer.
"The results of this study confirm that the decision to administer chemotherapy in node-negative estrogen receptor-positive breast cancer patients should no longer be based solely on traditional clinical and pathologic criteria, but also by integrating...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-11-25)
More Articles from Cancer Weekly
- Louisiana State University Health Sciences Center
LSUHSC public health contributes to estimate of HPV-related cancers - Breast Cancer
Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test - Cancer Vaccines
HIV'S disguises no match for Bionic Assassins - Cancer Vaccines
New research on cancer vaccines from National Cancer Institute summarized - Cancer Vaccines
Research in the area of cancer vaccines reported from University of California - Cancer Vaccines
Scientists at University of Pennsylvania, Medical Department detail research in cancer vaccines - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
